Trevi Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Trevi Therapeutics

16/03/2023 21:02

* Trevi Therapeutics Inc  TRVI.OQ  reported a quarterly
adjusted
loss of 6 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 10 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Trevi Therapeutics Inc's reported EPS for the quarter was
a loss
of 6 cents​.
    * The mean earnings estimate of analysts had fallen by
about 15.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Trevi Therapeutics Inc shares had fallen by 5.2% this
quarter.
    * The company reported a quarterly loss of $5.5 million.
    * Wall Street's median 12-month price target for Trevi
Therapeutics Inc is $8.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 16 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.10          -0.06          Beat
 Sep. 30 2022      -0.13          -0.12          Beat
 Jun. 30 2022      -0.18          -0.14          Beat
 Mar. 31 2022      -0.29          -0.24          Beat